Izumi Nishino
Toshima, 1708633, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials.
Journal: BMC psychiatry
Published: July 16, 2021
Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 25, 2021
Drug-drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: April 29, 2021
Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 19, 2021
Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data.
Journal: Biopharmaceutics & drug disposition
Published: September 06, 2020
Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study.
Journal: Journal of psychiatric research
Published: March 05, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026